Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline
09 févr. 2022 18h00 HE
|
Decibel Therapeutics, Inc.
- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability...
Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
31 janv. 2022 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
CaptionCall Extends Audiology Scholarship Deadline
27 janv. 2022 10h05 HE
|
CaptionCall, LLC
SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Today, CaptionCall, the leading provider of captioned telephone service for hard-of-hearing people who need captions to use the telephone, announced...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
25 janv. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Occupational Health Market Size, $5,493.39 Million by 2028 Lead by Hearing Loss Due to Noise Segment, 3.2% CAGR - Exclusive Research Report by The Insight Partners
24 janv. 2022 06h17 HE
|
The Insight Partners
New York, Jan. 24, 2022 (GLOBE NEWSWIRE) -- According to our new research study on “Occupational Health Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type (Work Induced Stress,...
Otonomy Reports Corporate and Product Pipeline Update
06 janv. 2022 07h51 HE
|
Otonomy, Inc.
Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE...
Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference
04 janv. 2022 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
InnerScope Hearing Technologies (OTC: INND) CEO to Present at The Emerging Growth Conference on Jan. 5, 2022
03 janv. 2022 08h00 HE
|
InnerScope Hearing Technologies, Inc.
ROSEVILLE, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- InnerScope Hearing Technologies Inc. (OTC: INND) ("InnerScope"), an emerging and disruptive leader in the Direct-to-Consumer...
Otonomy to Participate in the H.C. Wainwright BioConnect Conference
03 janv. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board
06 déc. 2021 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...